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SHORT COMMUNICATION
Tumour marker antigens during menses and pregnancy
Y. Touitou, Y. Darbois, A. Bogdan, A. Auzeby & S. Keusseoglou
Department of Biochemistry, Faculte de Medecine Pitie-Salpetriere, 91 boulevard de l'Hopital, 75634 Paris Cedex 13, France.
The specificity of tumour markers in cancer is poor. Indeed,
a number of pathophysiological occurrences can induce
significant variations of tumour marker plasma
concentrations (Touitou & Bogdan, 1988a,b). The situations
resulting in false positive determination have thus to be kept
in mind to avoid any misinterpretation in the follow-up of
the patients. It has been recently reported that in women,
CA 125 plasma concentrations increased during pregnancy
(Niloff et al., 1984) and menstruation (Haga et al., 1986;
Jager et al., 1988). Although infrequent, pregnancy does
occur in women with a cancer. Therefore, we have
documented the serum concentrations of a set of routinely
determined tumour markers (CEA, CA-125, CA-19.9, CA-
15.3 and SCC) in healthy pregnant women taking into
account the stage of pregnancy and in young women at two
stages of their menstrual cycle.
A transverse study was carried out on 100 unselected
pregnant women. Blood samples were obtained at the time
of routine examinations during pregnancy. The subjects were
grouped according to the stage of pregnancy (weeks of
amenorrhea), i.e. 8.5-13 weeks: 32 women (mean age:
29.2+0.9); 13.5-26 weeks: 32 women (mean age: 27.8+1.1)
and 26.5-42 weeks: 36 women (mean age: 30.6+0.6). A
parallel study was carried out on 22 young women
volunteers (medical students, mean age: 21.8 + 1.4) with blood
samplings at day 2 and day 9 of their menstrual cycle.
Venous blood samples (without anticoagulant).were drawn
under standardised conditions without haemolysis, from the
antecubital vein and the serum centrifuged. The serum
aliquots were kept at -20°C until assayed. Commercial kits
were used for the determination of the following tumour
markers: SCC (RIA, Abbott), CEA (EIA, Abbott), CA-125,
CA-19.9 and CA-15.3 (IRMA, CIS). The assays were
performed in the same series to avoid inter-assay variations.
The intra-assay coefficient of variations (n =30) were as
follows: CEA, 7.1% at 3ngml-1; CA-125, 8.7% at
45Uml-P; CA-19.9, 7.1% at 25Uml-'; CA-15.3, 3.5% at
25Uml-1; SCC, 11.3% at 3ngml-1. Statistical analysis was
performed using Student's t test (two-tailed).
In the 22 young control women the plasma concentrations
of tumour markers at day 2 were all within the normal range
except for CA-19.9, which was found abnormally hig1* in
three cases (range 43-65 Uml-1). No changes were observed
at day 9 when compared to day 2 (Tables I and II).
In pregnant women the plasma concentrations of the
markers were, as a rule, found within the normal range
except two slightly elevated SCC (2.3 and 2.5ngml-1) and
especially ten CA-19.9 (38-117Uml-1), i.e. for this latter:
three cases (9.4%) ranging from 38 to 434Uml- in the first
trimester, five cases (15.6%) ranging from 47 to 67 Uml-1 in
the second trimester and two cases (5.6%) with values of 71
and 117 Uml-1 in the third trimester of pregnancy. CA-15.3
plasma concentration was found to increase significantly
(from 11.1+4.2 to 17.0 +5.0; mean+s.d.) with the stage of
pregnancy (Tables I and II). SCC plasma concentration was
also significantly higher in the second and third trimesters
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(1.25 and 1.10ngml-P respectively) when compared to the
first trimester of pregnancy (0.77ngml-1). The CA-125
determination showed four cases (12.5%) with elevated
concentrations in the first trimester of pregnancy, one (3.1%)
in the second trimester and three (8.3%) in the third
trimester.
All the tumour markers documented in this report are of
common use in monitoring cancers, namely breast (CA-15.3
and CEA), ovarian (CA-125), pancreatic (CA-19.9), colon
and rectum cancers (CEA and CA-19.9) and squamous cell
carcinomas, e.g. uterine cervix (SCC). We report here the
effect of menses on the mean plasma concentrations of CA-
125 in 10 healthy young women, i.e. a rise' at day 2
(15.4Uml-1) when compared with day 9 (9.7Uml-1). We
could thus confirm the results from Pittaway & Fayez
(1987), who reported in nine women an increase from
13 +3 Uml -1 (days 23-26 ofcycle) to 29+7Uml -1 (days 2-4
of cycle) of CA-125 plasma concentrations. However, neither
in the women studied by these authors nor in those studied
here did this increase reach the cut-off level of 35Uml-1.
All the other documented markers were not found modified
during menses.
This transverse study on pregnant women allowed us to
show that CA-15.3 and SCC plasma concentrations
increased significantly during pregnancy although remaining
within the normal range. No differences could be seen
between the three stages of pregnancy for plasma mean
concentrations of the other documented tumour markers
(CEA and CA-19.9).
Nevertheless it has to be emphasised that 10% of the
studied pregnant women had abnormally high CA-19.9
plasma concentrations (38-117Uml-1), without any
apparent relation to the stage of pregnancy. In the same
way, three control women (13.6%), in apparent good health,
had abnormally high plasma concentrations of this marker
(43-65Uo-.1). CA-19.9 is a poorly specific marker since
plasma concentrations have been reported to be increased in
a number of non-malignant diseases (Touitou & Bogdan,
1988a). In the present study we could not attribute the
observed increases to any detectable benign pathology. The
determination of plasma concentrations of CA-125 in
pregnant women confirmed the rise of plasma CA-125
reported in the literature: Nilof et al. (1984) found elevated
levels of this marker in six out of 38 women (16%) in the
first trimester of pregnancy, whereas Halila et al. (1986) and
Pittaway & Fayez (1987) found respectively 11 out of 46
(24%) and three out of 15 women (20%) with increased CA-
125 plasma levels, disregarding the stage of pregnancy.
In conclusion, CA-125, CA-15.3 and SCC appear to
deserve special attention when documented in pregnant
women, and CA-19.9 seems to be very sensitive to benign
diseases and care should be given to the interpretation of
results of this tumour marker.
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Table I Tumour markers in pregnancy and in non-pregnant women at two stages of their menstrual cycle
Age CEA CA 15.3 CA 125 SCC CA 19.9
n (years)±s.d. (ngml-1)+s.d. (Uml 1)±s.d. (UmU1-)±s.d. (ngml ')±s.d. (Um1U')±s.d.
Pregnancy in weeks of
amenorrhea
413 32 29.2+4.9 0.65+0.35 11.1+4.2 b 23.7+13.91b 0.77+0.60 1 17.8+11.0
13.5-26 32 27.8+6.4 0.59+0.21 14.2+5.11 14.8+8.0 1 1.25+0.371 18.8+17.3
26.5-42 36 30.6+3.4 0.57+0.23 17.0±5.0{j 22.1+17.1] 1.10+0.56 J 16.7+20.8
Control women during
menstrual cycle
Day 2 22 1.11+0.71 12.9+4.1 15.4+7.6d 1.80+0.44 22.7+16.9
21.8+6.1
Day 9 22 1.04+0.66 12.2+3.4 9.7±5.Od 1.71+0.39 22.9+14.5
Means are different (two-tailed t test) with: aP<0.05; bP<0.01; cP<0.001; dTen subjects only.
Table II Percentage of false positive rate of tumour marker
antigens in pregnancy and during menses
Number (and percentage) of subjects above the
cut-off value
n CEA C4,-15.3 CA-125 SCC CA-19.9
Pregnancy in weeks of
amenorrhea
All 100 0 0 8(8.0) 2(2.0) 10(10.0)
< 13 32 0 0 4(12.5) 0 3(9.4)
13.5-26 32 0 0 1(3.1) 1(3.1) 5(15.6)
26.5-42 36 0 0 3(8.3) 1(2.8) 2(5.6)
Control women 22 0 0 1(10.0)a 0 3(13.6)
aTen subjects only.
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